MedTrace Logo

Helicobacter Pylori Eradication Study

NCT03130452 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 423

Last updated 2025-05-01

No results posted yet for this study

Summary

The purpose of this study was to evaluate the efficacy and compliance of tailored therapy which using the polymerase chain reaction for point mutation of clarithromycin, compared to concomitant therapy, in patients without history of H. pylori eradication.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Lansoprazole 30mg

lansoprazole 30 mg tablet

DRUG

Amoxicillin 1.0g Tab

Amoxicillin 1.0g tablet

DRUG

Clarithromycin 500mg

Clarithromycin 500mg tablet

DRUG

Metronidazole 500 mg

Metronidazole 500 mg tablet

Sponsors & Collaborators

  • Inje University

    lead OTHER

Principal Investigators

  • Ji Hyun Kim · Inje University Busan Paik hosipital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-17
Primary Completion
2019-01-28
Completion
2019-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03130452 on ClinicalTrials.gov